评估在儿童的甲甲酸不耐受性与morphea的评估
Jeanine McColl1, Ronald M Laxer1, Elena Pope2
1Division of Rheumatology (JM, RML), Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada.
概括
甲索酸不耐受性影响20.8%的儿科患者,皮下注射显著增加了风险. 青少年异常性关节炎/膜炎患者的不耐受率最高.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 儿科皮肤病学 儿科皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲托雷克萨特是儿童皮肤病学中常见的免疫抑制剂.
- 青少年异形性关节炎 (JIA) 中甲酸不耐受的患病率很高 (25-75%),但对形状性关节炎的数据缺乏.
- 这项研究调查了儿科形态病患者的甲状腺素不耐受性.
研究的目的:
- 确定在患有形态性疾病的儿童中甲状腺素不耐受症的流行率.
- 通过比较Morphea,JIA/uveitis和其他炎症性皮肤疾病之间的不耐受率.
- 确定儿科患者中甲状腺素不耐受症的预测因素.
主要方法:
- 符合条件的患者 (2-18岁) 服用甲状腺素3个月或更长时间治疗形状,炎症性皮肤病或JIA/膜炎.
- 甲甲酸不耐受性严重性评分 (MISS) 评估了不耐受性.
- 单向ANOVA和多变量回归分析了跨疾病和共变量的MISS.
主要成果:
- 在48名儿科患者中,整体不耐受性患病率为20.8%.
- 皮下用甲状腺素剂量 (平均MISS 6.78) 显示不耐受性高于口服剂量 (平均MISS 2.5).
- 关节炎/膜炎患者有最高的不耐受性 (37.5%),其次是形状 (20%) 和炎症性皮肤疾病 (5.9%).
结论:
- 甲索酸不耐受性在儿科患者中普遍存在,特别是那些患有JIA/膜炎的患者.
- 皮下给药是唯一发现的甲状腺素不耐受性风险增加的预测因子.
- 进一步的研究应该探索疾病活动和干预措施以减轻不耐受性.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:17Phase II Reactions: Methylation Reactions
193
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
193